Showing 1-10 of about 217 articles.
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will...
Portola Pharmaceuticals, Inc.
– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage – – Data Featured in an Oral Presentation at the 5th European Stroke Organisation...
Portola Pharmaceuticals, Inc.
– First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya®; Staged Commercial Launch Planned in Second Half of 2019 –...
Portola Pharmaceuticals, Inc.
– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalizedwith Life-Threatening Bleeding – – Initial Launch in Select Countries to Begin 2H 2019 – SOUTH SAN FRANCISCO,...
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Dr. John Curnutte, M.D., Ph.D., Executive Vice President and Head...
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer,...
Portola Pharmaceuticals, Inc.
– Fourth Quarter Andexxa® Revenues of $14.0 Million; Third Consecutive Quarter of Strong Revenues – – Received Positive CHMP Opinion on Ondexxya™; European Commission Decision Anticipated in Early...
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it has entered into a $125 million loan agreement with HealthCare...
Showing 1-10 of about 217 articles.
